Please note that this meeting will take place as an in-person event in Boston, Massachusetts and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Friday, July 24

• Networking Breakfast
• Biotech Spotlight 2-3
  • Novel Therapeutics
  • Novel Technologies
• Keynote Lecture
• Plenary Sessions 5-6
  • Plenary Session 5: Degraders in the Era of Precision Oncology
  • Plenary Session 6: From RAS Inhibitors to RAS Degraders
• Closing

Networking Breakfast

7-8 a.m. | Independence Ballroom West

Biotech Spotlight Session 2: Novel Therapeutics

8-9:30 a.m.

Biotech Spotlight Session 2: Novel Therapeutics

Grand Ballroom
Moderators: Christiana Bardon, MPM BioImpact, Boston, Massachusetts, Michael A. Caligiuri, City of Hope National Medical Center, Duarte, California, and William N. Hait, Johnson & Johnson (ret.), New Brunswick, New Jersey

• 8 a.m. | Introduction
• 8:05 a.m. | Arvinas, New Haven, Connecticut
  Keith Hornberger
• 8:25 a.m. | Xilio Therapeutics, Waltham, Massachusetts
  Uli Bialucha
• 8:45 a.m. | Pliant Therapeutics, South San Francisco, California
  Chris Barnes
• 9:05 a.m. | EvolveImmune Therapeutics, Branford, Connecticut
  Jay Fine

Biotech Spotlight Session 3: Novel Technologies

Constitution Ballroom A
Moderators: Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts and Benjamin Haibe-Kains, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada

• 8 a.m. | Introduction
• 8:05 a.m. | Insilico Medicine, Cambridge, Massachusetts
  Halle Zhang
• 8:25 a.m. | Auransa, Palo Alto, California
  Pek Lum
• 8:45 a.m. | Deep Origin, South San Francisco, California
  Max Ratnikov
• 9:05 a.m. | Pathos AI, Chicago, Illinois
  Jeremy Grubbs

Break

9:30-9:45 a.m. | Grand Ballroom Prefunction

Keynote Lecture

9:45-10:45 a.m. | Grand Ballroom

• 9:45 a.m. | Introduction
  Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
• 9:50 a.m. | Keynote Lecture
  Genetics as the Rosetta stone for cancer therapeutics
  William G. Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts
• 10:30 a.m. | Q&A

Break

10:45-11 a.m. | Grand Ballroom Prefunction

Plenary Sessions 5-6

11 a.m-1 p.m.

Plenary Session 5: Degraders in the Era of Precision Oncology

Grand Ballroom
Session Chair: Danette Daniels, Foghorn Therapeutics, Cambridge, Massachusetts

• 11:05 a.m. | First-in-class selective ARID1B degraders for the treatment of ARID1A mutant cancers
  Marina Nelen, Foghorn Therapeutics, Cambridge, Massachusetts
• 11:25 a.m. | Translating TPD from bench to bedside: The development of Setidegrasib (ASP3082) and key lessons
  Chinatsu Sakata, Astellas, Ibaraki, Japan
• 11:45 a.m. | Induced proximity: Any target, every time
  Ryan Potts, Amgen, Thousand Oaks, California
• 12:05 p.m. | RIPTACs: A Novel, powerful modality to treat patients with prostate cancer and other diseases
  David Puleo, Halda Therapeutics, New Haven, Connecticut
• 12:25 p.m. | Panel Discussion

Plenary Session 6: From RAS Inhibitors to RAS Degraders

Constitution Ballroom A
Session Chair: Rona Yaeger, Memorial Sloan Kettering Cancer Center, New York, New York

• 11:05 a.m. | Eliminating the oncogenic driver: Advancing targeted degradation of KRAS
  Kathryn Smith, Arvinas, New Haven, Connecticut
• 11:25 a.m. | KRAS – Degrading the undruggable
  Andreas Mantoulidis, Boehringer Ingelheim, Vienna, Austria
• 11:45 a.m. | Novel molecular glue degraders to target KRAS mutants
  Anita C. Bellail, HB Therapeutics, Indianapolis, Indiana
• 12:05 p.m. | Redefining RAS targeting: The next generation of therapeutic strategies
  Ignacio Garrido-Laguna, Moffitt Cancer Center, Tampa, Florida
• 12:25 p.m. | Panel Discussion
  Additional Panelist:
  Terri D. Conneran, KRAS Kickers, Charlotte, North Carolina

Closing Comments and Departure

1 p.m.